Althea Technologies to produce lead drug for Quintessence
Althea Technologies has been chosen by Madison's Quintessence Biosciences to produce its lead protein oncology drug for forthcoming clinical trials. The drug candidate, QBI-139, has proven to be effective in fighting cancer in various solid tumors and soon may be the subject of clinical trials. ...